Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vicus Therapeutics

Vicus Therapeutics
2005 FOUNDED
OOB STATUS
1-10 EMPLOYEES
Out of Business LATEST DEAL TYPE
Description

Provider of cancer treatment therapies intended to bring breakthrough immunotherapies to patients with cancer. The company's services mainly focus on offering a drug product that is controlled-release formulation of propranolol, a non-selective β-blocker, and etodolac, a COX-2 selective inhibitor, for combination with PD-1 inhibitors, enabling patients to get affordable access to lung cancer treatment therapies for advanced stage.

Website
Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 55 Madison Avenue
  • Suite 400
  • Morristown, NJ 07960
  • United States

+1 (973) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vicus Therapeutics’s full profile, request a free trial.

Vicus Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Feb-2019 00.000 Completed Out of Business
4. Angel (individual) 12-Aug-2010 00000 00.000 Completed Startup
3. Angel (individual) 09-Jul-2009 00000 00.000 Completed Startup
2. Angel (individual) 06-Aug-2008 $800K $1.6M Completed Startup
1. Angel (individual) 27-Jul-2007 $800K $800K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »